Shanghai, China, February 05, 2013 --(PR.com
)-- The global pharmaceutical industry is experiencing the important structural reform. In recent years, though the sales volume rises, the profit space sharply shrinks. Though the sales amount of 10 major pharmaceutical enterprises globally rose by 13% from 2009 to 2010, the profit fell by 4%, which was equivalent to about EUR 34 billion (Roland Berger).
Due to the rise in price pressure, change in system, laws and regulations of medical insurance and more stringent examination and approval procedures for launching new pharmaceuticals, pharmaceutical markets in Europe, the United States, etc. are stalling. However, there is a strong growth momentum in emerging markets. Even so, the profit still slightly declines, which comes from non-patent protection products to a great extent.
In the coming years, high-growth emerging markets will be the main force promoting the rise in global pharmaceutical markets. By 2016, the average annual growth rate of international pharmaceutical product markets will reach 4.5%, of which that of emerging markets is close to 12%. In particular, growth rates of pharmaceutical markets in China, Brazil, India and Russia will be far higher than the average. On the whole, the market share of emerging markets in the global pharmaceutical industry will reach about 40% by 2016.